These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

535 related articles for article (PubMed ID: 37298631)

  • 21. Systematic review of recent advancements in antibody-drug and bicycle toxin conjugates for the treatment of urothelial cancer.
    Domb C; Garcia JA; Barata PC; Mendiratta P; Rao S; Brown JR
    Ther Adv Urol; 2024; 16():17562872241249073. PubMed ID: 38779496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
    Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
    BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis.
    Dannehl D; Jakob D; Mergel F; Estler A; Engler T; Volmer L; Frevert ML; Matovina S; Englisch A; Tegeler CM; Rohner A; Seller A; Hahn M; Pfister K; Fink A; Popp I; Lorenz S; Tabatabai G; Juhasz-Böss I; Janni W; Brucker S; Taran FA; Hartkopf A; Schäffler H
    ESMO Open; 2024 May; 9(5):102995. PubMed ID: 38636292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody-drug conjugates for urothelial carcinoma.
    Thomas J; Sun M; Getz T; Ho B; Nauseef JT; Tagawa ST
    Urol Oncol; 2023 Oct; 41(10):420-428. PubMed ID: 37419845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance.
    Chen M; Huang R; Chen R; Pan F; Shen X; Li H; Rong Q; An X; Xue C; Shi Y
    Oncologist; 2024 Aug; 29(8):e957-e966. PubMed ID: 38574190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antibody-drug conjugates in breast cancer: the chemotherapy of the future?
    Nicolò E; Zagami P; Curigliano G
    Curr Opin Oncol; 2020 Sep; 32(5):494-502. PubMed ID: 32657795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Chinese expert consensus of antibody-drug conjugate toxicity management for breast cancer].
    ;
    Zhonghua Zhong Liu Za Zhi; 2022 Sep; 44(9):913-927. PubMed ID: 36164692
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel ADCs and combination therapy in urothelial carcinoma: latest updates from the 2023 ASCO-GU Cancers Symposium.
    Yu J; Wu S; Li R; Jiang Y; Zheng J; Li Z; Li M; Xin K; Guan X; Li S; Chen X
    J Hematol Oncol; 2023 Jul; 16(1):85. PubMed ID: 37507780
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System.
    Cecco S; Puligheddu S; Fusaroli M; Gerratana L; Yan M; Zamagni C; De Ponti F; Raschi E
    Target Oncol; 2024 May; 19(3):435-445. PubMed ID: 38696126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antibody-Drug Conjugates for Breast Cancer Treatment: Emerging Agents, Targets and Future Directions.
    Yang T; Li W; Huang T; Zhou J
    Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569276
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
    Ferraro E; Drago JZ; Modi S
    Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma.
    McGregor BA; Sonpavde GP; Kwak L; Regan MM; Gao X; Hvidsten H; Mantia CM; Wei XX; Berchuck JE; Berg SA; Ravi PK; Michaelson MD; Choueiri TK; Bellmunt J
    Ann Oncol; 2024 Jan; 35(1):91-97. PubMed ID: 37871703
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
    Kim JH; Chang IH
    Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-specific antibody drug conjugates for cancer therapy.
    Panowski S; Bhakta S; Raab H; Polakis P; Junutula JR
    MAbs; 2014; 6(1):34-45. PubMed ID: 24423619
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The emerging role of antibody-drug conjugates in urothelial carcinoma.
    Lattanzi M; Rosenberg JE
    Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-Drug Conjugates in Uro-Oncology.
    Sigorski D; Różanowski P; Iżycka-Świeszewska E; Wiktorska K
    Target Oncol; 2022 May; 17(3):203-221. PubMed ID: 35567672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.